Research Study

A Phase 3 Open-label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects With Tyrosine Kinase 3 - Internal Tandem Duplication (FLT3-ITD) Positive Acute Myeloid Leukemia (AML) Refractory to or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation
Principal Investigator 
Donna E. Hogge

Overview

Body Locations and Systems 
Leukemia
Disorders and Conditions 
ClinicalTrials.gov# 
NCT02039726
Status 
Recruiting
Study Start/End 
Sep 19, 2014 to Jun 7, 2019
Locations 
Vancouver General Hospital
Name/Title 
Jill Clark, Research Nurse
Phone 
604-875-4111 ext.62887
Email Address 
jclark@bccancer.bc.ca
Purpose of Study 

The primary objective of the study is to determine whether quizartinib monotherapy prolongs overall survival (OS) compared to salvage chemotherapy in subjects with FMS-like tyrosine kinase 3 - Internal Tandem Duplication (FLT3-ITD) positive AML who are refractory to or have relapsed within 6 months, after first-line AML therapy.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.